Insider Selling: Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Sells $511,677.21 in Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) VP Padmanabh P. Bhatt sold 14,491 shares of the company’s stock in a transaction that occurred on Thursday, March 21st. The shares were sold at an average price of $35.31, for a total value of $511,677.21. Following the transaction, the vice president now directly owns 8,570 shares of the company’s stock, valued at $302,606.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $33.74 on Thursday. Supernus Pharmaceuticals, Inc. has a 12-month low of $21.99 and a 12-month high of $39.09. The business has a 50 day simple moving average of $30.06 and a 200 day simple moving average of $28.15.

Supernus Pharmaceuticals (NASDAQ:SUPN) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.39). The business had revenue of $164.30 million during the quarter, compared to the consensus estimate of $155.03 million. Supernus Pharmaceuticals had a return on equity of 0.14% and a net margin of 0.22%. The business’s quarterly revenue was down 1.8% compared to the same quarter last year. During the same period last year, the company earned $0.43 earnings per share. Equities research analysts anticipate that Supernus Pharmaceuticals, Inc. will post 1.16 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently issued reports on SUPN shares. Piper Sandler decreased their price objective on Supernus Pharmaceuticals from $45.00 to $41.00 and set an “overweight” rating for the company in a report on Wednesday, February 28th. StockNews.com raised Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, December 6th.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. boosted its stake in Supernus Pharmaceuticals by 2.3% during the 4th quarter. Vanguard Group Inc. now owns 6,214,731 shares of the specialty pharmaceutical company’s stock valued at $179,854,000 after purchasing an additional 142,551 shares in the last quarter. Wellington Management Group LLP bought a new position in Supernus Pharmaceuticals during the 4th quarter valued at $1,514,000. Congress Asset Management Co. MA boosted its stake in Supernus Pharmaceuticals by 0.4% during the 4th quarter. Congress Asset Management Co. MA now owns 920,808 shares of the specialty pharmaceutical company’s stock valued at $26,648,000 after purchasing an additional 3,644 shares in the last quarter. GSA Capital Partners LLP boosted its stake in Supernus Pharmaceuticals by 14.2% during the 4th quarter. GSA Capital Partners LLP now owns 8,325 shares of the specialty pharmaceutical company’s stock valued at $241,000 after purchasing an additional 1,038 shares in the last quarter. Finally, Townsquare Capital LLC boosted its stake in Supernus Pharmaceuticals by 25.0% during the 4th quarter. Townsquare Capital LLC now owns 30,226 shares of the specialty pharmaceutical company’s stock valued at $875,000 after purchasing an additional 6,054 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.